FDA Approves Revolution Medicines' RASONQUE for Metastatic Pancreatic Cancer
Event summary
- FDA approved Revolution Medicines' RASONQUE (daraxonrasib) for metastatic pancreatic cancer on August 26, 2026.
- RASONQUE reduced the risk of death by 60% compared to chemotherapy in the Phase 3 RASolute 302 trial.
- The drug is the first broad RAS-targeted medicine approved for pancreatic cancer.
- RASONQUE is available by prescription in the U.S. with support through the (ON)Path™ program.
The big picture
The approval of RASONQUE marks a significant milestone in the treatment of pancreatic cancer, a disease with limited therapeutic options and a high mortality rate. Revolution Medicines' success in targeting the RAS protein, a long-standing challenge in oncology, could pave the way for similar treatments in other RAS-driven cancers. The strategic validation of the company's RAS(ON) inhibitor platform may attract further investment and partnerships in the oncology space.
What we're watching
- Market Adoption
- How quickly physicians and patients will adopt RASONQUE as a new standard of care for metastatic pancreatic cancer.
- Regulatory Expansion
- Whether the EMA will follow the FDA's approval and expedite the review process for RASONQUE in Europe.
- Pipeline Progress
- The pace at which Revolution Medicines advances RASONQUE into other cancer indications, such as non-small cell lung cancer.
Related topics